FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057384628> ?p ?o ?g. }

• W2057384628 endingPage "3927" @default.
• W2057384628 startingPage "3919" @default.
• W2057384628 abstract "Abstract Objective To compare the effects of methotrexate (MTX), alone or in combination with intravenous (IV) methylprednisolone (MP) or infliximab, on magnetic resonance imaging (MRI)–detected synovitis, bone edema, and erosive changes in patients with early rheumatoid arthritis (RA). Methods Forty‐four patients with early RA were randomized to receive MTX alone (MTX group), MTX plus IV MP (IV MP group), or MTX plus infliximab (infliximab group), infused on day 0 and weeks 2, 6, 14, 22, 30, 38, and 46. Gadolinium‐enhanced MRI scans of the metacarpophalangeal joints, wrists, and metatarsophalangeal joints were performed at baseline, week 18, and week 52. Results Scores for MRI‐detected synovitis and bone edema improved over time in the 3 groups, with significantly lower synovitis scores in the infliximab group compared with the MTX group and significantly lower bone edema scores in the infliximab group compared with the MTX and the IV MP groups. Scores for MRI‐detected erosion significantly increased over time in all groups. There were no differences in erosion scores between the MTX group and the other groups. It is of note that patients treated with IV MP showed more significant progression in MRI‐detected erosions compared with patients treated with infliximab. At week 22, response rates according to the American College of Rheumatology 20% improvement criteria (ACR20), the ACR50, and the ACR70 were significantly higher in both the IV MP group and the infliximab group compared with the MTX group. At week 52, remission was achieved in 40% of patients in the MTX group and in 70% of patients in the IV MP and infliximab groups. Health Assessment Questionnaire scores improved significantly over time in all groups, with patients receiving IV MP experiencing significantly more improvement compared with patients treated with MTX alone. No severe side effects were observed, except 1 case of MTX‐related pneumonitis. Conclusion The combination of MTX and infliximab is superior to MTX alone for reducing MRI‐detected signs of synovitis and bone edema in patients with early RA. Progression of MRI‐detected erosion was greater in patients treated with MTX plus IV MP compared with that in patients who received MTX plus infliximab." @default.
• W2057384628 created "2016-06-24" @default.
• W2057384628 creator A5005399691 @default.
• W2057384628 creator A5006123817 @default.
• W2057384628 creator A5027317477 @default.
• W2057384628 creator A5029308372 @default.
• W2057384628 creator A5039171922 @default.
• W2057384628 creator A5059823367 @default.
• W2057384628 creator A5069467112 @default.
• W2057384628 creator A5074975000 @default.
• W2057384628 creator A5083576726 @default.
• W2057384628 creator A5090277186 @default.
• W2057384628 date "2007-11-29" @default.
• W2057384628 modified "2023-10-18" @default.
• W2057384628 title "Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone" @default.
• W2057384628 cites W1982348705 @default.
• W2057384628 cites W1985004174 @default.
• W2057384628 cites W1996389186 @default.
• W2057384628 cites W1996437423 @default.
• W2057384628 cites W1999777294 @default.
• W2057384628 cites W2000905503 @default.
• W2057384628 cites W2005429018 @default.
• W2057384628 cites W2006323210 @default.
• W2057384628 cites W2054076626 @default.
• W2057384628 cites W2068080319 @default.
• W2057384628 cites W2078046981 @default.
• W2057384628 cites W2091419870 @default.
• W2057384628 cites W2095493602 @default.
• W2057384628 cites W2110177517 @default.
• W2057384628 cites W2115068422 @default.
• W2057384628 cites W2152348310 @default.
• W2057384628 cites W2154341553 @default.
• W2057384628 cites W2156996668 @default.
• W2057384628 cites W2159106700 @default.
• W2057384628 cites W2165253571 @default.
• W2057384628 cites W2166909821 @default.
• W2057384628 cites W2168058439 @default.
• W2057384628 cites W2169077818 @default.
• W2057384628 cites W2323601729 @default.
• W2057384628 cites W2340084730 @default.
• W2057384628 doi "https://doi.org/10.1002/art.23055" @default.
• W2057384628 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18050189" @default.
• W2057384628 hasPublicationYear "2007" @default.
• W2057384628 type Work @default.
• W2057384628 sameAs 2057384628 @default.
• W2057384628 citedByCount "117" @default.
• W2057384628 countsByYear W20573846282012 @default.
• W2057384628 countsByYear W20573846282013 @default.
• W2057384628 countsByYear W20573846282014 @default.
• W2057384628 countsByYear W20573846282015 @default.
• W2057384628 countsByYear W20573846282016 @default.
• W2057384628 countsByYear W20573846282017 @default.
• W2057384628 countsByYear W20573846282018 @default.
• W2057384628 countsByYear W20573846282019 @default.
• W2057384628 countsByYear W20573846282020 @default.
• W2057384628 countsByYear W20573846282021 @default.
• W2057384628 countsByYear W20573846282022 @default.
• W2057384628 countsByYear W20573846282023 @default.
• W2057384628 crossrefType "journal-article" @default.
• W2057384628 hasAuthorship W2057384628A5005399691 @default.
• W2057384628 hasAuthorship W2057384628A5006123817 @default.
• W2057384628 hasAuthorship W2057384628A5027317477 @default.
• W2057384628 hasAuthorship W2057384628A5029308372 @default.
• W2057384628 hasAuthorship W2057384628A5039171922 @default.
• W2057384628 hasAuthorship W2057384628A5059823367 @default.
• W2057384628 hasAuthorship W2057384628A5069467112 @default.
• W2057384628 hasAuthorship W2057384628A5074975000 @default.
• W2057384628 hasAuthorship W2057384628A5083576726 @default.
• W2057384628 hasAuthorship W2057384628A5090277186 @default.
• W2057384628 hasBestOaLocation W20573846281 @default.
• W2057384628 hasConcept C126322002 @default.
• W2057384628 hasConcept C126838900 @default.
• W2057384628 hasConcept C126894567 @default.
• W2057384628 hasConcept C141071460 @default.
• W2057384628 hasConcept C143409427 @default.
• W2057384628 hasConcept C17991360 @default.
• W2057384628 hasConcept C198451711 @default.
• W2057384628 hasConcept C2777077863 @default.
• W2057384628 hasConcept C2777138892 @default.
• W2057384628 hasConcept C2777575956 @default.
• W2057384628 hasConcept C2779244835 @default.
• W2057384628 hasConcept C2780372218 @default.
• W2057384628 hasConcept C2781059491 @default.
• W2057384628 hasConcept C71924100 @default.
• W2057384628 hasConcept C90924648 @default.
• W2057384628 hasConceptScore W2057384628C126322002 @default.
• W2057384628 hasConceptScore W2057384628C126838900 @default.
• W2057384628 hasConceptScore W2057384628C126894567 @default.
• W2057384628 hasConceptScore W2057384628C141071460 @default.
• W2057384628 hasConceptScore W2057384628C143409427 @default.
• W2057384628 hasConceptScore W2057384628C17991360 @default.
• W2057384628 hasConceptScore W2057384628C198451711 @default.
• W2057384628 hasConceptScore W2057384628C2777077863 @default.
• W2057384628 hasConceptScore W2057384628C2777138892 @default.
• W2057384628 hasConceptScore W2057384628C2777575956 @default.
• W2057384628 hasConceptScore W2057384628C2779244835 @default.
• W2057384628 hasConceptScore W2057384628C2780372218 @default.
• W2057384628 hasConceptScore W2057384628C2781059491 @default.

• next